Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 8/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL4904523 | 0.93 | NISCH (0.49) | NISCHGAARCE1 | |
| SCHEMBL6747069 | 0.93 | NISCH (0.47) | NISCHGAATSHRRCE1 | |
| SCHEMBL4823981 | 0.85 | NISCH (0.56) | NISCHGAARCE1 | |
| Formic Acid SCHEMBL4813959 | 0.83 | NISCH (0.51) | NISCHGAATSHR | |
| Formic Acid SCHEMBL4820051 | 0.80 | NISCH (0.41) | NISCHGAATSHR | |
| SCHEMBL4815718 | 0.79 | NISCH (0.54) | NISCHGAATSHRMAOAMAOB | |
| Formic Acid SCHEMBL4915522 | 0.75 | NISCH (0.60) | NISCHGAA | |
| SCHEMBL6746697 | 0.74 | NISCH (0.58) | NISCHGAATSHR | |
| Formic Acid SCHEMBL4823088 | 0.72 | NISCH (0.67) | NISCHGAATSHR | |
| SCHEMBL6745147 | 0.71 | NISCH (0.47) | NISCHGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | NISCH 1934/4885GAA 2982/4885TSHR 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.